Key Points {#FPar1}
==========

A pharmacy-led criteria-for-use oritavancin pathway was initiated at a community hospital in the emergency department (ED) or observation unit (OBS) as a measure to avert hospital inpatient admissions of certain designated patients with ABSSSIs.Relative to standard practices, use of oritavancin in the ED or OBS setting for skin and skin structure infections may shorten LOS, defined as the total time in hours from presentation to the ED until discharge home, including time spent in the OBS or inpatient unit.Early directed oritavancin use was not found to result in increased 30-day subsequent readmissions and 30-day return ED visits relative to standard inpatient treatment with vancomycin.

Introduction {#Sec1}
============

Oritavancin is a novel lipoglycopeptide antibiotic that is FDA approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible gram-positive organisms such as *Staphylococcus aureus*,*Streptococcus* spp., and *Enterococcus faecalis* \[[@CR1]\]. Similar to vancomycin, oritavancin disrupts cell wall synthesis by inhibiting transpeptidation, but it has the additional benefit of increasing membrane permeability via improved binding site affinity \[[@CR2]\]. Relative to other antibiotics approved for the treatment of patients with ABSSSIs, the greatest distinguishing feature of oritavancin is its single fixed-dose treatment, with no requirement for therapeutic drug monitoring. In two phase III trials, a single IV dose of 1200 mg of oritavancin had comparable efficacy and safety to 7--10 days of vancomycin for the treatment of adult patients with ABSSSIs \[[@CR3], [@CR4]\].

Data indicate that many hospitalized ABSSSI patients have zero or few uncontrolled comorbid conditions and limited to no systemic signs and symptoms of infection, and are often solely admitted to receive IV antibiotics \[[@CR5], [@CR6]\]. The mortality rate is low among ABSSSI patients with no comorbidities, and effective outpatient treatment should be encouraged in order to reduce unnecessary costs and the healthcare burden on hospitals \[[@CR7]\]. Because of its single-dose therapy, it has been postulated that oritavancin could be used to shift the care of appropriate ABSSSI patients from the inpatient to the outpatient setting \[[@CR8]\]. Across the SOLO trials, 792 patients were treated solely in the outpatient setting, and very few patients in the oritavancin group (1.3%) required subsequent care in the inpatient setting post outpatient treatment \[[@CR9]\]. More recently, data from the Clinical and Historic Registry and Orbactiv Medical Evaluation (CHROME) postmarketing registry reported that over 85% of patients were treated in an outpatient infusion center, a positive clinical response was observed in 92.8% of patients, and microbial eradication was observed in 90.0% of patients with posttherapy cultures. Within 28 days following oritavancin administration, only 4 (3.6%) patients were hospitalized due to failed treatment for the index infection \[[@CR10]\].

At AdventHealth East Orlando (AHEO), a 295-bed community teaching hospital, a quality assurance study found that the majority of patients hospitalized at this institution with cellulitis-related diagnoses had an average length of stay (LOS) of 4.13 days and an average cost of care totaling \$5,600 USD per case. Consistent with other studies \[[@CR5]\], most hospitalized patients had limited disease severity and comorbid conditions, indicating that many of these patients could have been treated in the outpatient setting. Based on these findings, AHEO developed a pharmacy-led pilot for the use of oritavancin in the emergency department (ED) or observation unit (OBS) as a measure to avert hospital inpatient admissions in appropriate patients with ABSSSIs. The objective of this analysis was to evaluate the effectiveness of the pharmacy-led oritavancin pilot relative to patients with ABSSSI who met the criteria for the oritavancin but received vancomycin during the same timeframe.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

A retrospective cohort analysis of patients who presented to the ED or OBS with a skin and soft tissue infection at AHEO was performed from January 1, 2017 through December 31, 2017. Patients who received oritavancin in the ED or OBS as part of the pharmacy-led pilot (pilot group) were compared to patients who met the criteria for oritavancin use during the study period but received vancomycin therapy (standard of care group).

Description of the Pilot Group {#Sec4}
------------------------------

Pharmacists, in collaboration with ED providers, prospectively identified patients who met the prespecified criteria (Appendix A) to receive oritavancin by reviewing the ED track board and assessing the electronic medical record. Once it was confirmed that the patient met the qualifications to receive oritavancin, the pharmacist met with the patient to explain the medication and expectations for treatment. Following patient consent, the pharmacy prepared and dispensed oritavancin to the ED for the 3-h infusion time. Patients were discharged and the AHEO outpatient transitions of the care clinic called each patient within 5 days of discharge. At least three phone calls were placed to attempt to reach the patient, and the pharmacist was trained to instruct the patient to follow up with their physician or return to the ED if symptoms persisted after discharge or were becoming worse. Some patients who underwent incision and drainage were asked to return to the ED within 48 h for wound care at the physician's discretion.

Description of the Standard of Care Group {#Sec5}
-----------------------------------------

The standard of care group comprised patients who met the criteria for oritavancin use during the study period but received vancomycin in the ED and continued with vancomycin therapy. Only patients with an ICD-10 code on the Medicines Company list of indications approved for their drug replacement program were included in the pilot group (Table [5](#Tab5){ref-type="table"} in Appendix B), so this criterion was used for inclusion in the standard of care group. A list of consecutive patients with these ICD-10 codes from January 1, 2017 through December 31, 2017 were screened. Patients were included in the standard of care group if they received vancomycin and met all study criteria (see the next section). The screening of consecutive patients for inclusion in the standard of care group was stopped once there were equal numbers of patients in the standard of care group and the pilot group.

Study Criteria {#Sec6}
--------------

For both the oritavancin pilot and standard of care groups, the criteria for entry into this analysis was as follows: ≥ 18 years old; had a proven or suspected gram-positive ABSSSI \[[@CR11]\] (i.e., skin infection with a total area of lesion plus surrounding erythema, edema, and/or induration of approximately ≥ 75 cm^2^); and met prespecified criteria for oritavancin use in the ED (Appendix A). Patients were excluded if they were pregnant; presented with sepsis, bacteremia, osteomyelitis, necrotizing fasciitis, endocarditis, or unstable vital signs; had a chronic infection such as diabetic foot infection or ulceration, infected burn, or decubitus ulcer; had a history of hypersensitivity to oritavancin; had a blood glucose  level of ≥ 300 mg/dL; or required unfractionated heparin sodium.

Data Elements {#Sec7}
-------------

Trained reviewers collected data from the patients' electronic medical records. Data elements that were extracted included demographics, comorbidities, length of hospitalization, antimicrobial medications, and causative pathogen for the ABSSSI. Demographic characteristics included age, sex, actual body weight, body mass index (BMI), race, comorbidities, and whether the patient was febrile on admission or met SIRS criteria \[[@CR12]\]. The investigators chose to use SIRS criteria in keeping with the institution's sepsis alert criteria, and to correlate with outcomes of the SOLO trials and a previous internal analysis of inpatient use of oritavancin. Comorbidities that were collected included the Charlson Comorbidity Index (CCI) \[[@CR13]\] and an active or recent history of IV drug abuse, diabetes, hepatitis, an immunocompromised state (including the presence of human immunodeficiency virus, HIV), renal insufficiency (defined as a glomerular filtration rate of \< 50 ml/min/1.73 m^2^) \[[@CR14]\], and severe peripheral vascular conditions. These covariates were selected based on those studied in the SOLO trials. For patients with microbiologic cultures, results were assessed for the presence of *S. aureus* and whether the pathogen was methicillin susceptible. Admission to the OBS or inpatient unit and discharge from the ED, OBS, or inpatient unit were all determined by the treating physician; neither the pharmacy nor investigators were involved in this process.

Clinical Outcomes {#Sec8}
-----------------

The following clinical outcomes were assessed: mean index hospital LOS, 30-day subsequent readmissions (all cause and infection related), and 30-day return ED visits (all cause and infection related). LOS was defined as the total time in hours from presentation to the ED until discharge home, including time spent in the OBS or inpatient unit. Readmission included all patients who were admitted to the hospital within 30 days of their initial presentation and treatment and were then assessed for cause of readmission. ED return looked at all patients who returned to the ED within 30 days, regardless of whether they were readmitted to the hospital or discharged home from the ED. For both 30-day subsequent readmissions and return ED visits, patients who returned for any infection were considered to be ID related, whereas those who returned for the index infection were considered to be patients with a recurrent ABSSSI. Patients who returned due to the physician's instructions on wound care were also recorded. Additionally, a follow-up via phone call was conducted for patients in the pilot program to assess their current status, as described previously.

Cost savings were assessed primarily as the number of days of inpatient admission avoided. This number was calculated as the difference in total LOS between all patients in the standard of care group and all patients in the pilot group. The overall cost saved by inpatient admission avoidance was based on an average cost per day of \$1,355.93 USD as determined by an internal review of the cost per case and the average LOS for the ABSSSI diagnosis-related group (DRG). Insurance reimbursement was recorded during the chart review, as was the number of patients who underwent drug replacement. Cost savings for drug replacement included all patients with a successful drug replacement by the manufacturer, and were determined based on the cost of the medication at this facility.

Statistical Analysis Plan {#Sec9}
-------------------------

Categorical variables were compared using Fisher's exact test, and continuous variables were compared using Student's*t* test or the Mann--Whitney *U* test. A Kaplan--Meier analysis was used to assess the primary endpoint of LOS. Stratified analyses were performed to check for the presence of effect modification or confounding. Two variables, presence of SIRs and CCI score (0--1 vs. ≥ 2), were evaluated in stratified analyses. A multivariate analysis was performed using generalized linear regression with gamma and loglink to determine the adjusted LOS when controlling for baseline differences between the two groups.

Results {#Sec10}
=======

During the study period, 122 patients met the study criteria, 61 patients received oritavancin, while the remaining 61 patients received the standard of care with vancomycin. Comparisons of baseline characteristics between the oritavancin group and the standard of care group are shown in Table [1](#Tab1){ref-type="table"}. The two groups had similar demographic characteristics with a few exceptions. The standard of care group had a greater portion of patients with BMI ≥ 30 kg/m^2^ (30 vs 19; *p* \< 0.01), but there was no statistical difference between the groups in the average BMI for all patients (31.9 vs 29.9; *p* = 0.27) or average body weight (95.39 kg vs 88.2 kg; *p* = 0.22). The standard of care group also had a higher number of diabetic patients (18 vs 6; *p* \< 0.01). In addition, it had a higher mean CCI (1.1 vs 0.54; *p* \< 0.01), likely due to the increased number of patients with peripheral vascular disease (16 vs 3; *p* \< 0.01), since there was no difference between the groups in the number of patients with preexisting hepatitis, renal insufficiency, or an immunocompromised state. The standard of care group had more febrile patients (10 vs 3; *p* = 0.02), but there was no significant difference between the groups in the number of patients who met the SIRS criteria (16 vs 10; *p* = 0.08). The standard of care group also had a lower proportion of patients with IV drug abuse (IVDA) (12 vs. 21; *p* \< 0.01).Table 1Comparison of baseline demographics and clinical features between the pilot and standard of care groupsPilot group (*n* = 61)Standard of care group (*n* = 61)*P* valueAge (years) Mean (SD)41.8 (14.9)47.16 (14.3)0.05  ≥ 65 years (*n* \[%\])7 (11.5)6 (9.8)0.69Gender (*n* \[%\]) Male36 (59)41 (67.2)0.17Race (*n* \[%\]) White51 (83.6)49 (80.3)0.52 Black2 (3.3)4 (6.6)0.3 Other8 (13.1)8 (13.1)1Body weight (kg) Mean (SD)88.2 (31.8)95.39 (31.5)0.216Body mass index (kg/m^2^) Mean (SD)29.9 (10.5)31.9 (9.3)0.267  \< 25 kg/m^2^ (*n* \[%\])21 (34.4)15 (24.6)0.06  ≥ 30 kg/m^2^ (*n* \[%\])19 (31.1)30 (49.2) \< 0.01Past medical history (*n* \[%\]) Diabetes mellitus6 (9.8)18 (29.5) \< 0.01 Hepatitis6 (9.8)7 (11.5)0.17 Immunocompromised1 (1.6)1 (1.6)1 Renal insufficiency6 (9.8)5 (8.2)0.67 Severe peripheral vascular conditions3 (4.9)16 (26.2) \< 0.01 IV drug abuse21 (34.4)12 (19.7) \< 0.01Charlson Comorbidity Index (CCI) Mean (SD)0.54 (0.93)1.1 (1.27) \< 0.01Confirmed pathogen during admission (*n* \[%\]) *S. aureus*5 (33.3)18 (41.9)0.08 MSSA1 (6.7)5 (11.6)0.13 MRSA4 (26.7)13 (30.2)0.45 Other2 (13.3)11 (25.6) \< 0.01 No cultures46 (75.4)18 (29.5) \< 0.01Patient presentation (*n* \[%\]) Febrile3 (4.9)10 (16.4)0.02 Meeting SIRS criteria10 (16.4)16 (26.2)0.08*IV* intravenous, *MRSA* methicillin-resistant *Staphylococcus aureus,* *MSSA* methicillin-sensitive *Staphylococcus aureus, SD* standard deviation, *SIRS* systemic inflammatory response syndrome

With regards to microbiologic data, the standard of care group had more patients with positive cultures. This was likely because more cultures were drawn in the standard of care group than in the pilot group (no cultures drawn: 18 vs 46; *p* \< 0.01). There was no statistical difference between the groups in the rate of *S. aureus* infection, nor when the infections were categorized into methicillin-sensitive *Staphylococcus aureus* (MSSA) or methicillin-resistant *Staphylococcus aureus* (MRSA) infections. There was a higher incidence of positive cultures due to other infections (11 vs 2; *p* \< 0.01) in the standard of care group, which may be due to the small sample size of cultures in the pilot group.

Outcome comparisons are shown in Table [2](#Tab2){ref-type="table"}. Administration of oritavancin in the ED and OBS (pilot group) was associated with a decreased mean LOS relative to the standard of care group (19.5 vs. 85.98 h, *p* \< 0.01). Figure [1](#Fig1){ref-type="fig"} shows the results of the Kaplan--Meier analysis, which demonstrated a statistically significant decrease in median LOS for the pilot group (13.25 vs 72 h, respectively, *p* \< 0.01). Three patients in the pilot group were hospitalized after they were administered oritavancin in the OBS, which deviated from the pilot protocol and may have led to a longer average LOS. A multivariate regression analysis adjusting for baseline variables showed that the average LOS for the pilot group was still decreased compared to the standard of care group (37.73 vs 159.41, *p* \< 0.01). Additionally, a stratified analysis resulted in a statistically significant decrease in LOS for patients with and without positive SIRS criteria, and in patients with CC ≤ 1 and CCI \> 1 (Table [3](#Tab3){ref-type="table"}).Table 2Comparison of outcomes between the pilot and standard of care groupsPilot group (*n* = 61)Standard of care group (*n* = 61)*p* valueLOS, measured in hours Mean (SD)19.5 (20.7)85.98 (50.34) \< 0.0130-day inpatient readmission (*n* \[%\]) All cause6 (9.8)6 (9.8)1 ID related5 (8.2)3 (5.9)0.24 Recurrent ABSSSI2 (3.3)3 (5.9)0.5530-day ED return (*n* \[%\]) All cause15 (24.6)18 (29.5)0.40 ID related7 (11.5)4 (6.6)0.12 Recurrent ABSSSI4 (6.6)3 (5.9)0.55 Wound care2 (3.3)4 (6.6)0.30*ABSSI* acute bacterial skin and skin structure infection, *ED* emergency department, *ID* infectious disease, *LOS* length of stay, *SD* standard deviationFig. 1Kaplan--Meier analysis of length of stay (measured in hours) for the pilot and standard of care groups. *LOS* length of stay (defined as the total time in hours from presentation to the emergency department until discharge home, including the time spent in the observation unit or inpatient unit)Table 3Comparison of outcomes between the pilot and standard of care groups stratified by the presence of systemic inflammatory response syndrome (SIRS) and the Charlson Comorbitidy Index (CCI) scorePresence of SIRsPilotStandard of care*p*-value(*n* = 10)(*n* = 16)Mean (SD) LOS, measured in h13.6 (8)78.2 (38.5) \< 0.0130-Day readmission (*n* \[%\])1 (10)1 (6.3)30-Day ED return (*n* \[%\])1 (10)2 (14.3)Absence of SIRsPilotStandard of care*p*-value(*n* = 51)(*n* = 45)Mean (SD) LOS, measured in h20.6 (22.2)88.8 (53.7) \< 0.0130-Day readmission (*n* \[%\])5 (9.8)5 (11.1)30-Day ED return (*n* \[%\])14 (27.5)16 (35.6)CCI score ≤ 1PilotStandard of care*p*-value(*n* = 55)(*n* = 43)Mean (SD) LOS, measured in h20.3 (21.6)85.4 (48.6)*P* \< 0.0130-Day readmission (*n* \[%\])5 (9.1)4 (9.3)30-Day ED return (*n* \[%\])13 (23.6)15 (34.9)CCI score \> 1PilotStandard of care*p*-value(*n* = 6)(*n* = 18)Mean (SD) LOS, measured in h11.4 (2.2)86.2 (51.1) \< 0.0130-Day Readmission (*n* \[%\])1 (16.7)2 (11.1)30-Day ED Return (*n* \[%\])2 (33.3)3 (16.7)*ED* emergency department, *h* hours, *LOS* length of stay, *n* number, *SD* standard deviation

The rates of subsequent all-cause 30-day readmissions were identical for the pilot and standard of care groups (6 patients in each group, 9.8% readmission rate), and the recurrent ABSSSI 30-day readmission rates were also comparable. In the oritavancin pilot, two patients returned due to a worsening of the infection---one after refusing wound wrapping after incision and drainage, and the other after reporting improvements for the first 2 weeks before symptoms returned. Two additional patients were asked to return due to positive blood cultures for *S. aureus*, since the pilot was only approved for the treatment of ABSSSI. Similarly, return ED visits within 30 days were comparable between groups; however, some patients in the oritavancin pilot were asked to return to the ED for wound care. These patients were included in our 30-day ED return data as they are included in our hospital's metrics.

Nineteen patients from the pilot group were reached via phone for follow-up from a total of 36 patients that had documented follow-up upon chart review. Three patients returned to the ED before a call was placed, and the remaining patients did not have any documentation of a follow-up phone call. All 19 patients reported an improvement, and 17 of those had no further complaints. Two patients still had some symptoms, though they reported that those symptoms were improved by their visits. Those patients were instructed to follow up with their primary care provider or to return to the ED if the symptoms persisted or worsened. Neither of those patients returned to the ED.

Cost savings were found to be \$308,000 USD based on the avoidance of 227 days of inpatient admissions at initial presentation (Table [4](#Tab4){ref-type="table"}). These savings were derived from the average cost of care for cellulitis patients and the corresponding LOS, and do not include liability or iatrogenicity.Table 4Financial outcomes of the oritavancin pilotCost savings due to hospital admission avoidance (*N* = 55)\*Days227Cost saved (US dollars)\$308,000\*6 of 61 patients were readmitted within 30 days to the inpatient unit after receipt of oritavancin and discharge from the emergency department. Savings were calculated using an average cost of \$5600 per cellulitis diagnosis-related group and an average length of stay of 4.13 days (internal data)

Discussion {#Sec11}
==========

Patients with ABSSSIs are largely treated with oral antibiotics in the outpatient setting or with IV antibiotics as inpatients, who are often dosed multiple times a day for an extended duration. For patients who fail outpatient treatment, the next step is typically hospital inpatient admission to receive IV treatment for multiple days \[[@CR15]\]. This practice places a significant cost burden on the patient and the utilization of healthcare resources, as each ABSSSI-related hospital admission is estimated to cost between \$6000 and \$20,000 USD \[[@CR5], [@CR16], [@CR17]\]. Due to the significant hospitalization costs associated with ABSSSI, and internally collected data suggesting that many ABSSSI patients are admitted unnecessarily, a pilot program was implemented at AHEO to administer oritavancin in the ED or OBS as a measure to avert hospital inpatient admissions in clinically stable ABSSSI patients.

Overall, the results suggest that using oritavancin in the ED or OBS unit to facilitate discharge to home may result in a decreased LOS relative to standard of care practices, although causality could not be established in this study due to its design. The findings also suggest that the use of oritavancin may not result in an increased rate of ED return visits. Although definitive conclusions cannot be drawn from the study, the collective results suggest that the primary financial benefit was was cost savings from reduced inpatient admission among the pilot group.

The findings from this study are largely comparable to those in several recent publications of real-world evidence. In an assessment of 67 patients who received oritavancin at a community hospital, no readmissions and 8 ED return visits were observed within 14 days of discharge \[[@CR18]\]. Similarly, the 30-day subsequent readmission rate was reported to be 6.1% in an evaluation of oritavancin for ABSSSI patients across three hospital-based outpatient infusion centers \[[@CR19]\]. In our study, the observed 30-day readmission rate was slightly higher (9.8%), but this may have been due to the aggressive mandated pharmacy callback system, which encouraged patients to return to the hospital if symptoms were not completely resolved. However, this readmission rate may also be representative of the patient population in this area of the city, as it was comparable to the readmission rate for the standard of care group.

Several aspects should be noted when interpreting these findings. First, this was a single-center retrospective cohort study, and it is therefore subject to all the limitations and biases associated with this design. Most notably, we cannot fully gauge the impact of prescribing bias on the observed findings. Inclusion in the pilot was dependent on the physician's knowledge of, and subsequent comfort with, the oritavancin pilot. Based on the author's interactions with the prescribers, many providers did not commonly prescribe oritavancin due to a lack of knowledge of the pilot or because they had forgotten about it. A total of 38 providers utilized the pilot protocol for the 61 patients included in the study. None of the prescriber(s) accounted for the majority of the orders. Twenty-three of these providers were ED providers, while the remainder were OBS or ID specialists. Inclusion in the standard of care cohort required the application of the same inclusion/exclusion criteria as used during the pilot, as this ensured the recruitment of patients who could have been included in the pilot had a more aggressive strategy been used to include every qualifying patient. Furthermore, oritavancin was primarily used in patients who were perceived as potentially noncompliant (IVDAs, the homeless, and those with social issues). It is unclear if or how providers' treatment preferences (i.e., prescribing bias) influenced the result.

The standard of care cohort group had higher CCI scores and more complicating comorbidities such as diabetes and peripheral vascular disease, and this may have contributed to their hospital LOS. However, no differences between the groups were observed in the stratified or multivariate analyses that looked at patients with varying CCI scores, providing further credence that oritavancin may decrease LOS. Furthermore, the observed LOS in the standard of care group was approximately 4 days, which is consistent with literature estimates \[[@CR5], [@CR16], [@CR17]\] and the internal quality assurance data collected prior to initiating the oritavancin pilot. Finally, unknown readmissions may have occurred outside the system. Subsequent readmission data were collected from within the same hospital system, and it is possible that some patients may have sought treatment at their primary care office or from another hospital system. Despite this, any missed subsequent readmissions were just as likely to occur in the pilot and standard of care treatment groups, so they would not have significantly altered the findings.

In conclusion, this study suggests that oritavancin may be administered in the ED or OBS to prevent unnecessary hospital inpatient admissions of stable ABSSSI patients without incurring increased readmission rates. Early directed oritavancin use was not found to result in increased 30-day subsequent readmissions and 30-day return ED visits relative to standard inpatient treatment with vancomycin. Additionally, the pilot program was associated with reduced costs. Patients in other studies have reported a preference for receiving ABSSSI treatment in the outpatient setting rather than hospitalization \[[@CR20]\]. Oritavancin has the potential to shift ABSSSI care from the inpatient to the outpatient setting, which could improve the patient's experience and satisfaction. However, as with all retrospective single-site studies, our findings should be interpreted cautiously and verified with a multicenter prospective study. Patient experience data should be included in all future studies as part of the benefit--risk assessment, given the growing focus on patient-centeredness in health care.

Appendix A {#Sec12}
==========

AdventHealth oritavancin criteria for use policy.

Inclusion criteria:Treatment of known or suspected ABSSSI caused by susceptible isolates of gram-positive pathogens with at least one of the following:Failed oral therapy or not a candidate for oral therapySuspect patient noncompliance or poor patient reliability.

Exclusion criteria:Hemodynamically unstable, altered mental status, acute organ injurySuspicion of systemic infection including bacteremia, osteomyelitis, or endocarditisChronic infectionNeed for surgical intervention, necrotizing fasciitis, or orbital cellulitisSuspicion of gram-negative organism or failed outpatient IV gram-positive therapyOther factors requiring inpatient admissionDiabetic ketoacidosis or hyperosmolar hyperglycemic state (HHS)Concurrent use of intravenous unfractionated heparin sodium within 120 h (5 days).

Appendix B {#Sec13}
==========

See Table [5](#Tab5){ref-type="table"}Table 5ICD-10 diagnostic codes consistent with Orbactiv^®^ (oritavancin) indicationICD-10-CM diagnosis codesDiagnosis*Staphylococcus* A49.01Methicillin-susceptible*Staphylococcus aureus*, unspecified site A49.02Methicillin-resistant*Staphylococcus aureus* infection, unspecified site B95.62*Staphylococcus aureus* as the cause of diseases classified elsewhere (methicillin resistant) B95.61*Staphylococcus aureus* as the cause of diseases classified elsewhere (methicillin susceptible) B95.8Unspecified*Staphylococcus* as the cause of diseases classified elsewhere*Streptococcus* A49.1*Streptococcus* infection, unspecified site B95.0--B95.2, B95.4*Streptococcus*, as the cause of disease classified elsewhereOther infections A46Erysipelas L08.0--L08.1, L08.81--L08.89,  L08.9Other local infections of skin and subcutaneous tissue*Cellulitis* L03.211Cellulitis of face K12.2Cellulitis and abscess of mouth H05.011--H05.019Cellulitis of orbit, abscess of orbit H60.10--H60.13Cellulitis of external ear J34.0Cellulitis and abscess of external nose L03.221Cellulitis of neck L03.113--L03.114Cellulitis of upper limb L03.111--L03.114Cellulitis of axilla and upper limb L03.011--L03.019Cellulitis of finger N61Inflammatory disorders of breast (includes cellulitis/abscess breast) L03.311--L03.316, L03.319Cellulitis of trunk L03.317Cellulitis of buttock L03.119Cellulitis of unspecified part of limb L03.115--L03.116Cellulitis of lower limb N48.22Cellulitis of corpus cavernosum and penis L03.031--L03.039Cellulitis of toe L03.811--L03.818Cellulitis of other sites L03.90Cellulitis, unspecified*Abscess* L02.01Cutaneous abscess of face H00.031--H00.039Abscess and furuncle of eyelid H60.00--H60.03Abscess of external ear K12.2Submandibular abscess L02.11Cutaneous abscess of neck L02.411--L02.414Cutaneous abscess of axilla and upper limb L02.511--L02.519Cutaneous abscess of hand L02.211--L02.219Cutaneous abscess of trunk L02.31Cutaneous abscess of buttock L02.419Cutaneous abscess of limb, unspecified L02.415--L02.416Cutaneous abscess of lower limb L02.611--L02.619Cutaneous abscess of foot N48.21Abscess of corpus cavernosum and penis N76.4Abscess of vulva K61.0--K61.4Abscess of anal and rectal regions L02.811--L02.818Cutaneous abscess of other sites L02.91Cutaneous abscess, unspecified*Furuncle* L02.02Furuncle of face L02.12Furuncle of neck L02.421--L02.424Furuncle of axilla, upper limb L02.521--L02.529Furuncle of hand L02.221--L02.229Furuncle of trunk L02.32Furuncle of buttock L02.429Furuncle of limb, unspecified L02.425--L02.426Furuncle of lower limb L02.621--L02.629Furuncle of foot L02.821--L02.828Furuncle of other sites L02.92Furuncle, unspecified*Carbuncle* L02.03Carbuncle of face J34.0Carbuncle and furuncle of external nose L02.13Carbuncle of neck L02.431--L02.434Carbuncle of axilla, upper limb L02.531--L02.539Carbuncle of hand L02.231--L02.239Carbuncle of trunk L02.33Carbuncle of buttock L02.439Carbuncle of limb, unspecified L02.435--L02.436Carbuncle of lower limb L02.631--L02.639Carbuncle of foot L02.831--L02.838Carbuncle of other sites L02.93Carbuncle, unspecified.
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